v3.26.1
Segment Information (Tables)
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Schedule of Reportable Segment Financial Information
The following table summarizes the reportable segment's financial information:
Three Months Ended
March 31,
(dollars in millions)20262025
Revenue$15.6 $188.8 
Less:
Research and development expense
Vepdegestrant (ARV-471) (*)
8.9 24.1 
ARV-806 6.5 0.9 
ARV-1025.5 6.5 
ARV-3933.7 2.6 
Bavdegalutamide (ARV-110)0.2 1.1 
Other programs2.6 1.7 
Non program-specific external expense9.2 13.9 
Compensation and related personnel expense
(including stock-based compensation)		21.3 36.9 
Other research and development expense2.4 3.1 
Total research and development expense60.3 90.8 
General and administrative expense
19.1 26.6 
Other segment expense, net (**)0.1 — 
Income tax expense0.1 0.2 
Plus:
Interest income, net6.4 11.7 
Segment net (loss) income$(57.6)$82.9 
(*)    Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.
(**)    Includes realized gains/ losses on foreign currency transactions and gains/ losses on sale of marketable securities.